Tuesday, November 07, 2017 8:50:55 PM
Geo, LOL, just as I am figuring some sense about which way is up, you throw in a left curve... "don't trust both sides".
Hmmm.
So if we turn the clock back to February/March and try to consider who talked to who between PPHM, Ronin, Steve White, one can observe the following "stage setting props":
- Report that PPHM tech is benefiting treatment in subsets of patients from the halted PPHM trial.
- Ronin/White touring Avid facilities, telling PPHM to change their business plan to emphasize Avid
- Ronin started acquiring millions of shares to establish ownership position
- PPHM placing even more millions of shares to raise operating funds
- PPHM saying they are seeking to avoid doing a reverse split as long as they can to avoid NASDAQ delisting
- Halozyme sales slowed down, significantly slowing Avid sales and shifting PPHM away from "self funding" goal.
- Halozyme raising operational funding, reported as successful
- Halozyme customers cross over to include potential PPHM collaborating Pharma
- Investor suit before Delaware Court citing Board overcompensation, abuse of authority. Laster decision trims back compensation in July
- Proxy fight gets underway to replace PPHM Directors with Ronin proposed candidates
- Complaints filed with SEC and CA AG office, citing overcompensation of PPHM Directors
- PPHM technology postured as "worthless" by some as others question halting PPHM tech development
- a 4+ million share short interest gets reported by NASDAQ in February that gets reported as covered four to six weeks later.
- pps and trading volume reported on NASDAQ shows major shifts at timing aligned with the short interest changes
All this and more. Through it all, I still look from the perspective of a "Long 2 investor" wondering what a "Long 1 investor" hedge/investment fund is going to do different to PPHM's business plan if they succeed in replacing the PPHM Board.
Best wishes and IMO.
KT
Hmmm.
So if we turn the clock back to February/March and try to consider who talked to who between PPHM, Ronin, Steve White, one can observe the following "stage setting props":
- Report that PPHM tech is benefiting treatment in subsets of patients from the halted PPHM trial.
- Ronin/White touring Avid facilities, telling PPHM to change their business plan to emphasize Avid
- Ronin started acquiring millions of shares to establish ownership position
- PPHM placing even more millions of shares to raise operating funds
- PPHM saying they are seeking to avoid doing a reverse split as long as they can to avoid NASDAQ delisting
- Halozyme sales slowed down, significantly slowing Avid sales and shifting PPHM away from "self funding" goal.
- Halozyme raising operational funding, reported as successful
- Halozyme customers cross over to include potential PPHM collaborating Pharma
- Investor suit before Delaware Court citing Board overcompensation, abuse of authority. Laster decision trims back compensation in July
- Proxy fight gets underway to replace PPHM Directors with Ronin proposed candidates
- Complaints filed with SEC and CA AG office, citing overcompensation of PPHM Directors
- PPHM technology postured as "worthless" by some as others question halting PPHM tech development
- a 4+ million share short interest gets reported by NASDAQ in February that gets reported as covered four to six weeks later.
- pps and trading volume reported on NASDAQ shows major shifts at timing aligned with the short interest changes
All this and more. Through it all, I still look from the perspective of a "Long 2 investor" wondering what a "Long 1 investor" hedge/investment fund is going to do different to PPHM's business plan if they succeed in replacing the PPHM Board.
Best wishes and IMO.
KT
